| Cat.No. | Name | Information |
|---|---|---|
| M14204 | Verapamil | Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. |
| M7409 | Thapsigargin | Thapsigargin is an endoplasmic reticulum (ER) stress inducer, it is also an inhibitor of microsomal Ca2+-ATPase. |
| M5073 | (R)-(+)-BAY K 8644 | (R)-(+)-BAY K 8644 is a calcium channel inhibitor, inhibits Ba2+ currents (IBa) with IC50 of 975 nM. |
| M3807 | Ionomycin (Calcium salt) | Ionomycin is a calcium ionophor and an antibiotic produced by Streptomyces conglobatus. |
| M3621 | Ionomycin | Ionomycin is a calcium ionophor and an antibiotic produced by Streptomyces conglobatus. |
| M3424 | Nifedipine | Nifedipine (BAY-a-1040) is a potent vasodilator agent with calcium antagonistic action. |
| M59017 | Diltiazem | Diltiazem is an orally active L-type Ca2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. |
| M59009 | L-Phenylalanine-d8 | L-Phenylalanine-d8 is the deuterium labeled L-Phenylalanine. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. |
| M58230 | CBD3063 | CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles. |
| M55537 | Clevidipine-d7 | Clevidipine-d7 |
| M52798 | Maurocalcine | Maurocalcine is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. |
| M39020 | Yangambin | Yangambin is a selective PAF receptor antagonist, inhibits Ca2+ influx through voltage-gated Ca2+ channels. Yangambin exhibits the antiallergic activity against β-hexosaminidase release with an IC50 of 33.8 μM and for anti-inflammatory activity with an IC50 of 37.4 μM. |
| M31233 | ω-Agatoxin IVA | ω-Agatoxin IVA is a potent, selective P/Q type Ca2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. |
| M31232 | ω-Agatoxin IVA TFA | ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. |
| M30966 | Suvecaltamide | Suvecaltamide (MK-8998; compound 33) is a potentially best-in-class, potent, selective modulator of T-type calcium channels (Cav3) for studies related to neurological disorders such as Parkinson's disease. |
| M30885 | Ziconotide acetate | Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research. |
| M27923 | Ulixacaltamide | Ulixacaltamide (Z944) is an orally active T-type calcium channel antagonist that rescues impairments in crossmodal and visual recognition memory. |
| M27832 | Mirogabalin besylate | Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of voltage-gated calcium channels, with Kds of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively. |
| M27758 | Ziconotide | Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research. |
| M27606 | Lercanidipine | Lercanidipine is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
